Hummer Financial Advisory Services Inc Sells 300 Shares of Johnson & Johnson (NYSE:JNJ)

Hummer Financial Advisory Services Inc decreased its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 2.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,953 shares of the company’s stock after selling 300 shares during the quarter. Johnson & Johnson accounts for about 2.2% of Hummer Financial Advisory Services Inc’s portfolio, making the stock its 5th largest position. Hummer Financial Advisory Services Inc’s holdings in Johnson & Johnson were worth $1,944,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Family CFO Inc acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth about $26,000. RE Dickinson Investment Advisors LLC raised its position in shares of Johnson & Johnson by 163.3% during the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after purchasing an additional 98 shares during the period. Advanced Research Investment Solutions LLC raised its position in shares of Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after purchasing an additional 120 shares during the period. Professional Financial Advisors LLC raised its position in shares of Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after purchasing an additional 68 shares during the period. Finally, Joseph P. Lucia & Associates LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth about $38,000. Institutional investors and hedge funds own 68.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on JNJ. Morgan Stanley decreased their price objective on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating for the company in a report on Monday, September 12th. SVB Leerink decreased their price objective on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Citigroup decreased their price objective on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. UBS Group decreased their price objective on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Finally, Wells Fargo & Company increased their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $189.78.

Johnson & Johnson Stock Down 0.8 %

JNJ stock opened at $166.28 on Tuesday. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. The business has a 50 day moving average price of $168.96 and a two-hundred day moving average price of $174.33. The company has a market cap of $437.18 billion, a price-to-earnings ratio of 24.20, a P/E/G ratio of 2.99 and a beta of 0.61. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter in the prior year, the business earned $2.48 EPS. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 10.7 EPS for the current fiscal year.

Johnson & Johnson declared that its board has approved a stock buyback plan on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 1.2% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its shares are undervalued.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were issued a $1.13 dividend. The ex-dividend date was Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.72%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.